Cargando…
Cinaciguat ameliorates glomerular damage by reducing ERK1/2 activity and TGF-ß expression in type-1 diabetic rats
Decreased soluble guanylate cyclase activity and cGMP levels in diabetic kidneys were shown to influence the progression of nephropathy. The regulatory effects of soluble guanylate cyclase activators on renal signaling pathways are still unknown, we therefore investigated the renal molecular effects...
Autores principales: | Czirok, Szabina, Fang, Lilla, Radovits, Tamás, Szabó, Gábor, Szénási, Gábor, Rosivall, László, Merkely, Béla, Kökény, Gábor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593847/ https://www.ncbi.nlm.nih.gov/pubmed/28894114 http://dx.doi.org/10.1038/s41598-017-10125-3 |
Ejemplares similares
-
Cinaciguat prevents the development of pathologic hypertrophy in a rat model of left ventricular pressure overload
por: Németh, Balázs Tamás, et al.
Publicado: (2016) -
The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus
por: Mátyás, Csaba, et al.
Publicado: (2015) -
Sustained hyperosmolarity increses TGF-ß1 and Egr-1 expression in the rat renal medulla
por: Mózes, Miklós M., et al.
Publicado: (2017) -
Pharmacological preconditioning with the guanylate cyclase activator cinaciguat (BAY 58-2667) protects against reperfusion injury after cardiopulmonary bypass
por: Radovits, Tamás, et al.
Publicado: (2009) -
Custodiol-N, the novel cardioplegic solution reduces ischemia/reperfusion injury after cardiopulmonary bypass
por: Veres, Gábor, et al.
Publicado: (2015)